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Juvenile idiopathic arthritis-associated uveitis
Sarah L. N. Clarke1,2, Ethan S. Sen1,2* and Athimalaipet V. Ramanan1,2
Abstract
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood, with JIA-associated uveitis its
most common extra-articular manifestation. JIA-associated uveitis is a potentially sight-threatening condition and
thus carries a considerable risk of morbidity. The aetiology of the condition is autoimmune in nature with the
predominant involvement of CD4+ T cells. However, the underlying pathogenic mechanisms remain unclear,
particularly regarding interplay between genetic and environmental factors. JIA-associated uveitis comes in
several forms, but the most common presentation is of the chronic anterior uveitis type. This condition is usually
asymptomatic and thus screening for JIA-associated uveitis in at-risk patients is paramount. Early detection and
treatment aims to stop inflammation and prevent the development of complications leading to visual loss,
which can occur due to both active disease and burden of disease treatment. Visually disabling
complications of JIA-associated uveitis include cataracts, glaucoma, band keratopathy and macular oedema.
There is a growing body of evidence for the early introduction of systemic immunosuppressive therapies in
order to reduce topical and systemic glucocorticoid use. This includes more traditional treatments, such
as methotrexate, as well as newer biological therapies. This review highlights the epidemiology of
JIA-associated uveitis, the underlying pathogenesis and how affected patients may present. The current
guidelines and criteria for screening, diagnosis and monitoring are discussed along with approaches to
management.
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Background
JIA is the most common rheumatic disease of childhood,
with JIA-associated uveitis (JIA-U) its most frequent
extra-articular manifestation. Uveitis is the inflammation
of the uvea (comprising the iris, choroid and retina).
The Standardisation of Uveitis Nomenclature (SUN) cri-
teria are used to define the anatomical location and time
course of uveitis, allowing reproducible assessment and
monitoring of disease [1, 2]. The time course of uveitis
is defined as acute, subacute, chronic or recurrent and
anatomical location as anterior, intermediate, posterior
or panuveitis. Additionally, JIA-U can be unilateral or bi-
lateral, thus assessments are made of each eye in turn.
JIA-U most commonly presents as chronic anterior uve-
itis, which is often clinically silent. This form of uveitis
is most frequently associated with oligoarticular and
rheumatoid factor negative polyarticular categories of
JIA. In contrast, acute anterior uveitis, which is generally
symptomatic, unilateral and episodic, is seen particularly
in the enthesitis-related arthritis (ERA) category of JIA.
Early identification and treatment of JIA-U is important
given the risk of sight-threatening complications. Man-
agement of JIA-U includes the use of both topical and
systemic agents and is an active area of research.
Visually-disabling complications can occur both as a
result of chronic disease activity and treatment bur-
den (particularly topical glucocorticoids), and include
cataracts, glaucoma, band keratopathy and macular
oedema [3].
Epidemiology
Uveitis is predominantly a disease of adults, with chil-
dren representing approximately 5–10 % [4]. However,
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the risk of delayed diagnosis and onset of complications
at a young age makes this an important clinical problem.
The overall incidence of uveitis in the paediatric popula-
tion, reported in a study from Finland, was 4.3 per
100,000/year and prevalence of 27.9 per 100,000 [5].
When broken down by aetiology, the prevalence of
JIA-U among all causes of paediatric uveitis varies
widely by referral centre, ranging from 15–67 %
across centres in Europe, North America and Israel
[4, 6–9]. The variation in these figures may partly be
due to the referral cohorts from which the patients
are selected, however, it should also be noted that
uveitis can precede a diagnosis of arthritis in 3–7 %
of children with JIA [10] and thus children presenting
with uveitis need careful assessment for underlying
systemic or infectious disease. When looking specific-
ally at the prevalence of uveitis in those patients
already known to have JIA, estimates of prevalence
ranges from 11.6 % [11] to 30 % [12] although overall
it appears to be decreasing over the past decade.
Thus there is a well-established, reciprocal link between
JIA and uveitis; uveitis is a frequent finding in JIA patients
as well as JIA being a common underlying cause for the
condition in children.
Regarding disease pattern, in one study where
13.1 % of 1081 JIA patients developed uveitis, chronic
anterior uveitis was predominant (68.3 %) [13]. How-
ever, acute anterior disease (16.2 %), recurrent anter-
ior disease (12 %) and panuveitis (3.5 %) were also
encountered.
A number of risk factors for JIA-U have been iden-
tified. These include gender, JIA category, age of on-
set, and ANA and HLA-B27 positivity [3, 10, 12, 14].
A younger age, female gender, oligoarticular disease
and presence of ANA are risk factors for chronic an-
terior uveitis. In contrast, being male with HLA-B27
and ERA predispose to acute anterior uveitis. The
interplay between individual risk factors is likely to be
complex and inter-dependent. For example, in a
retrospective study of 1047 patients with JIA, the risk
of developing uveitis was age-dependent in girls, but
not boys [15]. The impact of ethnicity on JIA-U is
unclear. Early studies identified JIA-U in many differ-
ent ethnic groups and suggested ethnicity did not
play a role [16]. More recent studies have suggested
that those of European descent are at increased risk
of JIA-U compared to the at-risk local population
[17].
Pathogenesis
Despite the well-documented link between JIA and
uveitis, the reason for uveal inflammation is not well
understood. It is likely that the pathophysiology of
JIA-U involves both genetic and environmental
elements. The genetic basis for JIA-U is likely to be
complex; despite familial cases having been reported
[18], monogenic or Mendelian patterns of inheritance
have not been identified [19].
Most JIA-associated genes lie within the human
leucocyte antigen (HLA) region, and this association
supports the theory of JIA-U being an autoimmune
disorder. Studies looking at the association between
risk of JIA-U and HLA subtype have conflicted,
however HLA alleles which confer risk have been
identified when looking at HLA alleles within par-
ticular JIA categories. In patients with oligoarticular
JIA, chronic anterior uveitis has been associated
with the HLA-DR5 haplotype [20] and HLA-
DRB1*1104 allele [21]. In particular the combination
of HLA-DRB1*1104 and HLA-DPB1*0201 alleles is
linked with a 7.7-fold increased risk of chronic uve-
itis. HLA-B27 is classically seen in ERA and confers
an increased risk of acute anterior uveitis in this pa-
tient group [22]. HLA-DR1 is the only HLA allele
which has repeatedly been shown to be protective
against chronic anterior uveitis associated with JIA
[23]. Additionally, there is evidence that HLA asso-
ciations are temporal with HLA alleles conferring
protection or susceptibility to JIA at different ages;
some alleles confer protection in early children but
increase risk of JIA-associated uveitis in later child-
hood [24].
At the cellular level, there appears to be involvement
of both T and B lymphocytes in generating an immune
response against native intraocular antigens including
S-arrestin (also known as retinal S-antigen), retinol-
binding protein 3, and tyrosinase-related proteins
[25]. Evidence for the involvement of both B and T
lymphocytes comes from immunohistochemistry of
eye biopsies from patients with JIA which show a
predominance of CD4+ rather than CD8+ T lympho-
cytes as well as variable levels of CD20+ B lymphocytes.
CD4+ lymphocytes include pro-inflammatory Th1 cells
(producing interferon gamma) and Th17 cells (producing
interleukin-17), which are regulated by both CD4+CD25
+FoxP3+T regulatory cells (Tregs) and inducible Tregs.
It is likely that autoimmunity results from imbalance
between these cell subsets leading to loss of tolerance
to self-antigens. In addition to the adaptive immune
response, elements of the innate immune system have
also been implicated in the pathogenesis of JIA-U
[23].
The risk of chronic anterior uveitis in JIA patients
is increased in those who are also ANA positive
[26], raising the question as to whether ANAs are
pathogenic in, or an epiphenomenon of, JIA-U. The
specificity of the ANAs is not known although stud-
ies have previously shown higher frequency of anti-
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histone antibodies in JIA patients with uveitis com-
pared to those with no historic or current uveitis
[27, 28]. Another report, however, has not shown
temporal association between anti-histone antibodies
and the presence of uveitis [29]. Studies have been
undertaken to address the role of ANAs by using
immunofluorescence to detect antibody binding in
human eyes incubated with the sera from JIA pa-
tients versus sera from healthy controls. JIA patients
were shown to have increased frequency of anti-
bodies against the iris and retina [30]. Similar find-
ings were seen when looking at antibody binding
using JIA patient (with or without uveitis) and
healthy control sera in swine eyes. Walscheid et al.
showed predominant binding of antibody from JIA-U
patients to the iris and ciliary body [31]. Whether
these antibodies are a cause or an effect of uveitis
has not been elucidated by these studies, as they
used sera from patients with established disease. To
date, no specific intra-ocular antigen has been iden-
tified as the target for ANAs, and thus their role in
pathogenesis remains unclear.
Clinical features
Uveitis can present with overt symptoms as seen in
acute anterior uveitis. Typical features include eye
pain, redness, headaches, photophobia and visual
changes. However, chronic anterior uveitis, more
commonly seen in JIA, is often completely asymp-
tomatic. Hence, regular screening for uveitis in JIA
patients is essential to detect clinically-silent, but
potentially vision-threatening, disease. Even in the
presence of symptoms, children may be unable to re-
port reliably what they are experiencing, thus a need
for formal assessment of vision and ocular health
remains.
Sabri et al. found that the mean time from onset of
JIA to onset of uveitis was 1.8 years [13]. However,
uveitis can pre-date the diagnosis of JIA thus eye inflam-
mation can go unnoticed for a significant period. Add-
itionally, a recent study has suggested a biphasic course
for the condition with a second peak of disease activity
occurring around puberty [32] suggesting the need for
vigilance in monitoring these patients over time.
Diagnosis/Screening
All patients at risk of JIA-U should be screened for
the condition. Screening guidelines are available in
several countries including the UK [33]. The UK
guidelines are summarised in Box 1. The UK con-
sensus standard is for first ophthalmological assess-
ment to take place within 6 weeks of JIA being
diagnosed or suspected [34], underlining the im-
portance of diagnosing and treating this condition
promptly.
Box 1: British Society for Paediatric and Adolescent
Rheumatology/ Royal College of Ophthalmology guide-
lines for uveitis screening in JIA [33].
Screening of children with JIA for uveitis involves
a combination of slit lamp examination, measure-
ment of intraocular pressure and age-appropriate
visual acuity (VA) testing. A slit lamp allows examin-
ation of the anterior and posterior chambers as well
as the retina. A diagnosis of uveitis is made based
on features of inflammation on slit lamp examin-
ation. These include cells in the anterior chamber
(AC) [35] and AC flare resulting from protein leak-
age into the AC due to breakdown of the blood–
aqueous humour barrier [36]. The SUN criteria pro-
vide a grading system for intra-ocular inflammation,
which takes into account AC cells, AC flare, vitreous
cells, and vitreous haze or debris (Box 2). The criteria also
provide definitions of improvement and worsening of the
condition (Box 2) allowing reproducible assessment and
monitoring of uveitis activity.
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Box 2: Standardisation of Uveitis Nomenclature (SUN)
criteria for uveitis activity [adapted with permission from
Elsevier © Jabs et al. Am J Ophthalmol 140, 509-16
(2005)[2]]
The measurement of intra-ocular pressure is import-
ant in patients with JIA-U as patients are at risk of intra-
ocular hypertension and glaucoma. This risk remains,
despite control of active inflammation, as illustrated by
one study showing the first measurement of raised intra-
ocular pressure at a time when the disease was inactive in
60 % of eyes [37]. Hence the need for regular measure-
ment of intra-ocular pressure during follow-up.
The assessment of VA provides a measure of both dis-
ease activity and visual damage resulting from both
chronic disease activity and failure or complications of
treatment. There are a number of structural complications
which occur in the setting of JIA-U which contribute to
visual loss. These include band keratopathy, posterior
synechiae, cataract, glaucoma, hypotony, macular oedema,
epiretinal membrane, and optic disc oedema. The need for
functional, age-appropriate assessment of vision during
uveitis screening has been highlighted by Heiligenhaus et
al. who have developed guidelines for measuring outcome
in JIA-U and included assessment of VA as a key outcome
measure [38].
Treatment
Central to the management of JIA-U is its early detec-
tion and appropriate assessment of disease activity. This
requires effective communication between paediatric
rheumatologists and ophthalmologists which may be
helped by organisation of multi-disciplinary clinics. The
aim of treatment is to achieve 0 cells in the anterior
chamber (SUN AC cell grade 0) in both eyes [39]. Prac-
tical management protocols have recently been pub-
lished both by our group in Bristol, UK [40] and an
interdisciplinary panel from Spain [39]. A modified algo-
rithm based on consensus guidelines [39–41] is provided
in Fig. 1. Topical glucocorticoids are used in the manage-
ment of acute anterior uveitis but all other treatments dis-
cussed below are in relation to chronic anterior uveitis.
Interdisciplinary guidelines on management of JIA-U
advise that therapy is initiated when the AC cell grade
is > 0.5+ [41]. Treatment is also indicated when there is
fibrin in the AC and keratocytic precipitates with corneal
oedema and loss of VA. Immunosuppressive treatment
should be intensified if there is failure to see improve-
ment in inflammation or presence of poor prognostic
factors. Heiligenhaus et al. identify these factors as poor
initial vision, cataract, macular oedema, dense vitreous
body opacification, ocular hypotony and glaucoma. Cata-
ract, glaucoma, synechiae and band keratopathy alone,
in the absence of active uveitis, do not require anti-
inflammatory treatment [41].
Topical glucocorticoids
The first line treatment for both acute and chronic
anterior uveitis is topical glucocorticoids [41–43]. The
greatest efficacy is seen with high potency steroids such
as prednisolone acetate 1 % or dexamethasone phos-
phate 0.1 % used once daily to hourly depending on the
degree of inflammation [44]. Persistent treatment with
frequent steroid eye drops is associated with higher inci-
dence of cataracts. In an observational study, treatment
of ≤ 3 drops daily of topical glucocorticoid was associ-
ated with an 87 % lower risk of cataracts than > 3 drops
daily (RR 0.13, 95 % CI 0.02–0.69; p = 0.02) [45].
Cycloplegics
Cycloplegics are used topically to prevent formation of
synechiae by dilating the pupil in patients without syne-
chiae or with grades 1–2 (up to 180°). Options include
tropicamide or cyclopentolate 0.5–1 % eye drops [39, 40].
Systemic and regional glucocorticoids
In severe or sight-threatening JIA-U, where rapid control
of intraocular inflammation is required, systemic gluco-
corticoids either orally (prednisolone 1–2 mg/kg/day) or
as intravenous pulse (methylprednisolone 20–30 mg/kg/
day for 1–3 days) are sometimes necessary [43]. Evidence
for their use derives only from adult studies [46, 47],
although they are listed as options in paediatric guidelines
[41]. Periocular or intraocular glucocorticoids are occa-
sionally used for severe uveitis. The well-known side
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effects of systemic glucocorticoids mandate weaning as
soon as possible with earlier introduction of steroid-sparing
immunosuppression in moderate to severe JIA-U [48].
Synthetic DMARDs
The primary indication for systemic immunosuppression
with one of the DMARDs is failure of adequate control
of inflammation after 3 months of topical treatment,
particularly with > 3 drops daily [41]. Recurrence of
disease when topical glucocorticoids are weaned is also
an indication for systemic therapy. Table 1 summarises
the range of non-biological immunosuppressants used to
treat JIA-U, their doses and evidence base. Evidence
comes predominantly from retrospective case series since
controlled clinical trials of the drugs in JIA-U have not
been undertaken.
Methotrexate (MTX) remains the first second-line
therapy after topical glucocorticoids. It is indicated after
12 weeks of topical treatment if there is no improvement
to AC cell grade ≤ 0.5+, or sooner if > 2 drops daily are
required, if there is worsening inflammation or if ocular
complications develop [39, 41]. A systematic review and
meta-analysis identified 9 eligible studies of methotrex-
ate in non-infectious uveitis including 135 patients of
Fig. 1 Treatment algorithm for chronic anterior uveitis associated with juvenile idiopathic arthritis. [Adapted with permission from Springer ©
Bou, R. et al. Rheumatol Int 35, 777–785 (2015) [36] and from Springer © Heiligenhaus, A. et al. Rheumatol Int 32, 1121–1133 (2012) [38]]. At all
stages aim to minimise topical steroid to≤ 2 drops/day while maintaining AC cell grade≤ 0.5+. * Mycophenolate mofetil (MMF) is a potential
alternative to a biologic drug if there is active uveitis but no active arthritis. Legend: AC: anterior chamber, d: days, h: hours, m: months, MTX:
methotrexate, po: by mouth, sc: subcutaneous, tx: treatment, VA: visual acuity, w: weeks
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whom 121 had JIA [49]. The dose of 15 mg/m2 once
weekly was most commonly used, with a maximum of
20 mg orally or 25 mg by subcutaneous injection [50].
The mean time to MTX-induced remission was reported
as 4.25 months with duration of remission of 10.3 months
[50]. In the systematic review, improvements in intraocu-
lar inflammation were seen in 73 % (95 % CI 67–81 %).
Adverse events, most commonly gastrointestinal discom-
fort, nausea and elevated liver enzymes, were experienced
in 19.6 % of patients where data were available [49]. MTX
treatment was associated with a reduced need for cataract
extraction, required in 29 % of treated patients compared
with 64 % of those never receiving MTX [51].
One study has reported on uveitis relapse after with-
drawal of MTX. Among 22 patients with JIA-U who
were treated with MTX, the drug was discontinued in
59 % because of inactive disease after a mean of 1.5 years
of inactivity and a total 3.1 years duration of therapy
[52]. Factors associated with significantly longer relapse-
free survival were: treatment > 3 years, age > 8 years
when MTX was withdrawn, and inactivity of uveitis for
longer than 2 years before withdrawal. One year increase
in duration of inactive uveitis before withdrawal of MTX
was associated with a decreased hazard of relapse of
93 %. It is recommended that MTX is continued for
at least 12 months once uveitis is inactive and for
24 months in those with poor visual prognosis [39].
Other DMARDs such as mycophenolate mofetil
(MMF), tacrolimus, azathioprine, and ciclosporin are
used less frequently in treatment of JIA-U [43, 53, 54].
Their use is detailed in Table 1. Leflunomide, which is
occasionally used to treat joint disease in JIA, has been
associated with more frequent uveitis flares compared
with MTX in one retrospective study [55]. Combinations
of two DMARDs (such as MTX and MMF) have been
tried in more resistant cases. However, we have previ-
ously reported that addition of a third immunosuppres-
sive agent has limited efficacy and is associated with
increased risk of infections [56]. Current treatment algo-
rithms recommend that if there is worsening disease or
failure to achieve AC cell grade 0 after 3–4 months on
MTX, then a biologic drug is added [39, 57].
Biologic drugs
Over the past decade, randomised controlled trials
(RCTs) of biologic agents have demonstrated their effi-
cacy in controlling joint disease in JIA [58]. The same
drugs have also been used in treatment of associated
uveitis (Table 2). The greatest evidence, thus far derived
from cohort studies and with RCTs underway, supports
the use of adalimumab in treatment of JIA-U. A double-
blind, placebo-controlled RCT of adalimumab was
stopped early due to efficacy after randomising 90 pa-
tients [59]. Analysis of the primary endpoint (“time to
treatment failure”) showed a positive effect in favour of
adalimumab with a hazard ratio of 0.27 (95 % CI 0.13–
0.52, p < 0.0001). Adverse events were noted in 88.3 % of
patients on adalimumab and 90 % on placebo, with in-
fections being the most common serious adverse event
in the treatment group.
In contrast to adalimumab, a double-blind RCT of
etanercept in 12 patients with JIA-U showed no differ-
ence between the drug and placebo [60]. With this small
number of patients, the study was powered to detect a
difference only if greater than 70 percentage points be-
tween treatment arms. Etanercept is not recommended
Table 1 Synthetic DMARDs used in treatment of chronic anterior uveitis associated with JIA
Drug name Mechanism Dosage and route Common side effects Evidence Key references
Methotrexate Cellular adenosine
release [95]
10–15 mg/m2
(or 0.3–0.6 mg/kg)
po or sc once weekly
GI discomfort, nausea,
elevated liver enzymes
Systematic review and
meta-analysis of retrospective
case series (n = 135):
improvement in 73 %
[49]
Azathioprine Purine nucleoside
analogue, inhibits
DNA replication
1 mg/kg od,
increasing to
maximum
3 mg/kg od
GI discomfort, bone
marrow suppression,
liver impairment
Retrospective case series
(n = 41): uveitis inactivity in
61.5 % as initial monotherapy;
66.7 % as combination therapy
[96]
Mycophenolate
mofetil
Inhibitor of inosine-5-
monophosphate
dehydrogenase
300 mg/m2 bd,
increasing to
600 mg/m2 bd
GI discomfort, leukopenia,
hair loss
Several retrospective case series
(n = 17, 52 and 85; not all with
JIA, variable outcome measures):
response in 55–88 %
[97–99]
Ciclosporin Calcineurin inhibitor
blocking T cell
proliferation
2.5–5 mg/kg/day
in 2 doses
GI disturbance, hypertension,
renal and liver dysfunction,
lipid abnormalities
Retrospective case series
(n = 82 and 14): uveitis inactivity
in 24 % as monotherapy,
48.6 % as combination therapy
[100, 101]
Tacrolimus Calcineurin inhibitor
blocking T cell
proliferation
50–150 microgram/
kg bd
GI disturbance, hypertension,
renal and liver dysfunction,
lipid abnormalities, blood
disorders
Retrospective case series (n = 62,
mostly adults with idiopathic uveitis):
permitted glucocorticoid tapering
and improved visual acuity
[102]
Legend: bd twice daily, GI gastro-intestinal, od once daily, po by mouth, sc subcutaneous
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in patients with JIA-U. A meta-analysis including 229
children with JIA-U has shown that infliximab and adali-
mumab have similar efficacy and both are superior to
etanercept [61]. However, during 40 months’ follow-up,
uveitis more commonly remained in remission in those
treated with adalimumab compared with infliximab
(60 % vs 18.8 % respectively) [62]. A small case series
has reported that switching between anti-TNF agents,
particularly from infliximab to adalimumab, can regain
control of uveitis [63]. There have been no systematic
studies of treatment options after failure of an anti-TNF
although other biologics are sometimes used. Experience
using abatacept, tocilizumab and rituximab for treatment
of JIA-U has been reported in case series (Table 2). Effi-
cacy was seen in most patients although only small
numbers have been reported.
The duration of maintenance therapy on biologic agents
is not certain although consensus recommendations sug-
gest continuing treatment for 24 months of inactive dis-
ease [39]. One retrospective cohort study (n = 50, 44 %
with JIA) has reported on uveitis reactivation after stop-
ping infliximab (n = 45) or adalimumab (n = 5) [64]. Of 19
patients who achieved remission and were subsequently
withdrawn from anti-TNFs, 63.8 % had reactivation within
12 months and there did not appear to be an association
with duration of medication-induced remission.
There are increasing data on the safety of biologic
drugs in JIA and rates of adverse events such as uveitis.
Several studies have reported flares or new-onset uveitis
while on etanercept [65–67]. Evidence from national
registries suggests that etanercept is associated with a
greater number of uveitis cases than adalimumab or
infliximab [68]. However, no definite causative effect of
etanercept can be proved from these retrospective obser-
vational studies and the prescribing pattern of the differ-
ent anti-TNFs may be a confounding factor [69]. A
German registry study (n = 3467 patients) suggested that
in those patients with a known negative past history of
uveitis the rate of a new uveitis event was 3.2/1000 pa-
tient years (PY) in the MTX group, 1.9/1000PY in the
etanercept monotherapy group and 0.9/1000PY in the
group on the combination of both [70]. An observa-
tional study reporting adverse events in JIA patients re-
ceiving biologics in Finland (n = 348 patients) reported a
rate of new-onset uveitis of 0.8/100PY, 0.3/100PY and
0.5/100PY while on etanercept, infliximab and adali-
mumab respectively [71]. The rates of uveitis flare were
2.8/100PY, 8.0/100PY and 3.8/100PY for each respective
treatment. The authors suggest that the apparently
higher rate of flare while on infliximab is because most
patients with a pre-existing diagnosis of uveitis were
started on this drug during the observation period
(1999–2009).
Surgical treatments
Several complications of uveitis, such as cataracts and
glaucoma, may require surgical treatment. Removal of
the lens by phacoemulsification is the usual surgical
treatment for a cataract that is impacting significantly
on visual acuity [72]. Complete control of intraocular
inflammation for at least 3 months prior to surgery is
associated with improved outcomes [73, 74]. Aggressive
Table 2 Biological immunosuppressants used in treatment of chronic anterior uveitis associated with JIA
Target Drug name Drug class Dosage and route Evidence Key references
TNFα Etanercept Dimeric fusion protein Not recommended for treatment
of JIA-U
RCT: no more effective than placebo.
Case reports of new uveitis on
etanercept
[60, 61]
Infliximab Chimeric (mouse-human)
mAb
6 mg/kg IV initially, then 3–10 mg/kg.
2nd dose at 2 weeks, then every
4–8 weeks depending on response
Several case series showing efficacy [61]
Adalimumab Fully human mAb 24 mg/m2 sc q2w Several case series showing efficacy.
RCTs in progress
[61, 90]
In practice often 20 mg sc q2w
(body weight <30 kg), 40 mg sc q2w
(body weight ≥30 kg)
Golimumab Fully human mAb 50 mg sc q4w Case series (n = 3) showing efficacy [103]
IL-6 Tocilizumab Humanised mAb 10 mg/kg (body weight <30 kg),
8 mg/kg (body weight >30 kg)
IV q4w
Case series (n = 3) and case report
showing efficacy. Phase II trial in
progress
[92, 93, 104, 105]
CD80/86
(CTLA4)
Abatacept Fully human fusion protein 10 mg/kg IV at weeks 0, 2, 4
then q4w
Case series (n = 7 and n = 2) showing
efficacy. Lack of sustained response
in severe uveitis (n = 21)
[94, 106–108]
CD20 Rituximab Chimeric (mouse-human)
mAb
375 mg/m2 or 750 mg/m2 IV,
two doses 2 weeks apart
Case series (n = 10 and n = 8 with
long-term follow-up) showing
efficacy in most patients
[109–111]
Legend: CTLA-4 cytotoxic T-lymphocyte-associated antigen 4, IL interleukin, IV intravenous, JIA-U juvenile idiopathic arthritis-associated uveitis, mAb monoclonal
antibody, od once daily, ow once per week, q2w every 2 weeks, q4w every 4 weeks, RCT randomised controlled trial, sc subcutaneous, TNF tumour necrosis factor
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courses of pre- and post-operative topical and systemic
glucocorticoids may be required to optimise surgical
results [40]. Surgical treatment may also be required
for glaucoma associated with JIA-U unresponsive to
pharmacological management. Interventional options
include goniotomy, insertion of a glaucoma drainage
device or trabeculectomy [75–77].
Prognosis
Chronic anterior uveitis associated with JIA is a sight-
threatening disease with ocular complications result-
ing from both the disease itself and its treatments.
Visual loss may be present at first assessment with
one study describing VA of 20/50 or worse in 40.3 %
and 20/200 or worse in 24.2 % at presentation [78].
A systematic literature review looking at outcomes in
JIA-U showed an adverse visual outcome (VA < 20/40
both eyes together) in 9.2 % of those with uveitis [3].
The main complications were cataracts, glaucoma and
band keratopathy occurring in 20.5, 18.9 and 15.7 %
respectively.
Several studies have looked at long-term follow-up.
Skarin et al. reported a cohort of 55 JIA-U patients
between 1973 and 1982 [79]. Seven years after uveitis
onset, 42 % had cataracts and 5 % glaucoma. At 24 years,
51 % had cataracts, 22 % glaucoma and 49 % had signs
of active uveitis or were receiving topical glucocorticoids
for recent flares. Similar persistence into adulthood of
asymptomatic uveitis in almost half of patients with
JIA-U was seen in a cohort of 19 subjects who were
born in 1976–1980 [80].
Several factors have been identified which are associ-
ated with a more severe course of uveitis and develop-
ment of complications [81–83]. These risk factors for
poor prognosis include: male gender; young age at onset
of uveitis; short duration between onset of arthritis and
development of uveitis; and presence of synechiae at first
diagnosis of uveitis. A retrospective case series including
65 children with JIA-U showed significantly worse VA in
boys versus girls at 1 year and 3 year follow-up [84].
Another study suggested that a shorter time interval
between arthritis and uveitis onset is the main predictor of
severity of uveitis [85]. Risk factors for visual loss, a key
long-term outcome, were examined in a retrospective
study with 596 affected eyes [78]. The overall incidence of
visual loss to 20/50 or worse was 0.18/eye year (EY). The
overall rate of developing a new ocular complication was
0.15/EY but significantly lower at 0.04/EY in those with
no complications at baseline. The same study also showed
bilateral uveitis, active uveitis (≥1+ AC cells or ≥ 0.5 vitre-
ous haze), longer duration of uveitis, presence of posterior
synechiae, abnormal intraocular pressure (IOP) and his-
tory of prior intraocular surgery were associated with
worse vision during follow-up.
There are suggestions that both JIA-U prevalence and
frequency of complications may be decreasing over time.
A prospective, cross-sectional study from Germany in-
cluding 18,555 JIA patients between 2002 and 2013
found a significant decrease in uveitis prevalence from
13.0 to 11.6 % [86]. There were also significant decreases
in uveitis complications from 33.6 to 23.9 % (OR 0.94,
p < 0.001). Over the same time period there were in-
creases in use of synthetic DMARDs (39.8 to 47.2 %)
and biologic DMARDs (3.3 to 21.8 %). Another study
compared a cohort of patients with JIA-U from 1990–
1993 (n = 239) with a 2000–2003 cohort (n = 240) and
found a frequency of complications of 35 and 21 % re-
spectively [87]. This apparent reduction may be related to
earlier use of systemic immunosuppression, such as
methotrexate, to treat joint disease. Evidence to support
this comes from a subgroup (n = 3512) of the German
2002–2013 JIA cohort with disease duration < 12 months
at first documentation and more than 2 years of follow-up
[88]. Compared to those with no DMARD treatment in
the year before uveitis onset, the risk of uveitis was signifi-
cantly decreased by methotrexate (hazard ratio [HR] 0.63,
p = 0.022), by TNF inhibitors (HR 0.56, p = 0.001) and by
a combination of the two (HR 0.10, p = 0.001). The use of
methotrexate early, specifically within the first year of JIA,
was associated with a clearly reduced risk of uveitis com-
pared with no early methotrexate (4.8 % vs 8.5 % respect-
ively; HR 0.29, p < 0.001).
Future directions
Better understanding of the pathogenesis of JIA-U may
help to identify biomarkers, either genetic or perhaps
plasma factors, which would allow stratification of pa-
tients to higher risk groups. These could be targeted
with earlier and more aggressive therapy.
Key to improvement of therapies is the effective trans-
lation from bench to bedside [89]. High quality evidence
for efficacy and safety of novel treatments specifically
within a JIA-U population is required. The SYCAMORE
study, a randomised placebo-controlled multicentre trial
of adalimumab for JIA-U has completed recruitment
and is now in follow-up [59, 90]. Another RCT of adali-
mumab is awaiting report from France [91]. The APTI-
TUDE trial, an open-label study of subcutaneous
tocilizumab for anti-TNF-refractory JIA-U is recruiting
patients in the UK [92]. There are also smaller studies
underway or planned examining tocilizumab and abata-
cept in JIA-U [93, 94].
Conclusion
JIA-associated uveitis is the commonest extra-articular
manifestation of JIA with significant numbers of children
still developing sight-threatening complications. Close
co-operation between paediatric rheumatologists and
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ophthalmologists and regular screening with slit lamp
examination is essential for early diagnosis. Growing
evidence supports the early use of systemic immunosup-
pression with the aim of quiescence of intraocular in-
flammation and avoidance of steroid-related side effects.
A range of biologic drugs are being used, mostly on the
basis of retrospective observational cohort studies, in
methotrexate-resistant or intolerant cases. Prospective
trials of adalimumab and tocilizumab which are now un-
derway will provide further evidence about their efficacy
and safety in treatment of JIA-U. A better understanding
of the immunopathogenesis and identification of predict-
ive biomarkers to target the widening therapeutic arma-
mentarium will be a key goal in the years to come.
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